Table 2.
Propensity score-matched baseline characteristics and SARS-CoV-2 infection test positivity between AAP and NSAIDs groups.
| Characteristic | AAP n = 529 |
NSAIDs n = 529 |
SMD |
|---|---|---|---|
| Sex, n (%) | 0.027 | ||
| male | 235 (44.4) | 242 (45.7) | |
| female | 294 (55.6) | 287 (54.3) | |
| Age, n (%) | 0.096 | ||
| 20–29 | 67 (12.7) | 75 (14.2) | |
| 30–39 | 64 (12.1) | 83 (15.7) | |
| 40–49 | 78 (14.7) | 84 (15.9) | |
| 50–59 | 101 (19.1) | 76 (14.4) | |
| 60–69 | 84 (15.9) | 94 (17.8) | |
| 70–79 | 84 (15.9) | 68 (12.9) | |
| 80– | 51 (9.6) | 49 (9.3) | |
| Region, n (%) | 0.091 | ||
| Seoul | 81 (15.3) | 71 (13.4) | |
| Gyeonggi | 143 (27.0) | 146 (27.6) | |
| Daegu | 77 (14.6) | 64 (12.1) | |
| Gyeongbuk | 60 (11.3) | 55 (10.4) | |
| Others | 168 (31.8) | 193 (36.5) | |
| HTN, n (%) | 184 (34.8) | 167 (31.6) | 0.069 |
| COPD, n (%) | 29 (5.5) | 34 (6.4) | 0.039 |
| Asthma, n (%) | 79 (14.9) | 94 (17.8) | 0.074 |
| CKD, n (%) | 34 (6.4) | 28 (5.3) | 0.050 |
| DM, n (%) | 126 (23.8) | 119 (22.5) | 0.032 |
| CVA, n (%) | 60 (11.3) | 60 (11.3) | 0.000 |
| Charlson Comorbidity Index, n (%) | 0.058 | ||
| 0 | 184 (34.8) | 201 (38.0) | |
| 1 | 90 (17.0) | 84 (15.9) | |
| 2 or more | 255 (48.2) | 244 (46.1) | |
| Current use of medication, n (%) | |||
| Steroid | 102 (19.3) | 105 (19.8) | 0.014 |
AAP: acetaminophen; NSAIDs: non-steroidal anti-inflammatory drugs; HTN: hypertension; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; DM: diabetes mellitus; CVA: cerebrovascular disease.